Mersana Therapeutics Inc.

0.52
-0.03 (-5.44%)
Jan 22, 2025, 3:39 PM - Market open
-5.44%
Bid 0.52
Market Cap 64.24M
Revenue (ttm) 35.07M
Net Income (ttm) -75.11M
EPS (ttm) -0.6
PE Ratio (ttm) -0.87
Forward PE -3.14
Analyst Buy
Ask 0.52
Volume 7,441,314
Avg. Volume (20D) 3,369,658
Open 0.54
Previous Close 0.55
Day's Range 0.52 - 0.55
52-Week Range 0.52 - 6.28
Beta 1.48

About MRSN

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development ...

Industry Biotechnology
Sector Healthcare
IPO Date Jun 28, 2017
Employees 123
Stock Exchange NASDAQ
Ticker Symbol MRSN

Analyst Forecast

According to 6 analyst ratings, the average rating for MRSN stock is "Buy." The 12-month stock price forecast is $6, which is an increase of 1053.85% from the latest price.

Buy 66.67%
Hold 33.33%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Mersana Therapeutics Inc. is scheduled to release its earnings on Feb 26, 2025, before market opens.
Analysts project revenue of $7.64M, reflecting a -28.6% YoY shrinking and earnings per share of -0.16, making a 0.00% YoY.
1 week ago
-44.62%
Mersana Therapeutics shares are trading lower. The... Unlock content with Pro Subscription
2 months ago
+19.55%
Mersana Therapeutics shares are trading higher after the company reported better-than-expected Q3 financial results.